Theratechnologies Inc. (TSE:TH) – Investment analysts at National Bank Financial cut their FY2018 EPS estimates for shares of Theratechnologies in a report issued on Tuesday. National Bank Financial analyst E. Leno now anticipates that the company will post earnings of $0.14 per share for the year, down from their previous estimate of $0.35. National Bank Financial has a “Outperform” rating and a $8.75 price target on the stock.
Separately, Scotiabank dropped their price target on Theratechnologies from C$10.00 to C$9.25 and set an “outperform” rating for the company in a research report on Friday, October 6th.
Theratechnologies (TSE TH) opened at C$6.43 on Friday. Theratechnologies has a 52 week low of C$2.61 and a 52 week high of C$8.72.
Theratechnologies Company Profile
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
What are top analysts saying about Theratechnologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Theratechnologies Inc. and related companies.